Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Lancet Oncol. 2020 Nov 27;22(1):107–117. doi: 10.1016/S1470-2045(20)30540-4

Figure 2: High-grade recurrence-free survival in patients with non-muscle-invasive bladder cancer given nadofaragene firadenovec, in patients who had a complete response at 3 months.

Figure 2:

(A) Patients with carcinoma in situ, with or without Ta or T1. (B) Patients with high-grade Ta or T1.